Content
All Posts > Content under Pharma/Biotech
IBB Is Positioned For Outperformance
Article By:
Andres Cardenal
Read
Friday, December 6, 2019 8:33 AM EDT
iShares Nasdaq Biotechnology ETF is benefitting from reduced regulatory risk in the middle term. The ETF is still trading below its highs of 2015, so it has a lot of ground to recover going forward.
Never Heard Of The NEO Exchange? You're Not Alone
Article By:
Lorimer Wilson
Read
Friday, December 6, 2019 6:35 AM EDT
More and more companies have raised capital through the public markets in Canada, leading to the existence of hundreds of publicly-traded cannabis stocks - and a relatively new stock exchange.
Clovis Oncology (CLVS) Buy Level Approaching
Article By:
Gareth Soloway
Read
Thursday, December 5, 2019 2:04 PM EDT
Shares of Clovis Oncology, Inc. (CLVS) continue to retrace the massive up-move seen recently.
In this article: CLVS
November Marijuana Market Performance Sliced & Diced By Segment
Article By:
Lorimer Wilson
Read
Thursday, December 5, 2019 4:42 AM EDT
Every month I slice and dice the performance of 6 categories within the overall cannabis market to unveil the strengths and weaknesses of its components and November saw a dramatic spread in the returns of those categories
Huge Biotech M&A Premiums Narrow Perception Gap
Article By:
Lipper Alpha Insight
Read
Wednesday, December 4, 2019 6:27 AM EDT
The premiums needed to seal biotechnology acquisitions have always been high, but they’ve reached the stratosphere this year
Pitfalls Of Biotechnology Investing
Article By:
Ketan Desai
Read
Tuesday, December 3, 2019 4:53 PM EDT
How capital distorts the availability of biotechnology companies.
In this article: IBB
Canopy Growth (CGC) Bull Flag Forming
Article By:
Gareth Soloway
Read
Monday, December 2, 2019 1:48 PM EDT
Shares of marijuana player Canopy Growth continue to trade sideways to lower after an over 50% surge just a couple weeks ago.
In this article: CGC
November Performance Of The Market's 15 Cannabis ETFs Ranged From +6.1% To -14.4%
Article By:
Lorimer Wilson
Read
Monday, December 2, 2019 4:36 AM EDT
The performance of the 15 marijuana/marijuana-related ETFs varies depending on their constituents. In November this segment of the cannabis market ranged from +6.1% to -14.4% (excluding the 2 leveraged ETFs) and declined, on average, 7.3% in total.
8 Monster Stock Market Predictions For The Week Of December 2
Article By:
Michael J. Kramer
Read
Sunday, December 1, 2019 11:49 AM EDT
It will be a busy week for economic data with the ISM reports and plenty of job data likely going to decide which way the markets go. But then again, the market knows weak data will force the Fed’s hand to take action.
Week In Review: Pharmaron, A Beijing CRO, Stages $434 Million Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, November 30, 2019 4:07 PM EDT
Pharmaron Beijing staged a $434 million Hong Kong IPO to expand its international CRO operations. In January, Pharmaron completed a $76 million IPO on the Shenzhen Exchange, and its stock price has quadrupled since its debut.
In this article: MRK
2 Names To Consider In A Heating Up Small-Cap Biotech Sector
Article By:
Scott Matusow
Read
Wednesday, November 27, 2019 8:30 AM EDT
The biotech sector has been heating up due to an increased risk appetite coming from additional market liquidity and a favorable Fed policy. Here, we highlight 2 early-stage biotech companies that we think can provide substantial upside.
Here Is The 14th Most Popular Stock Among 752 Hedge Funds
Article By:
Insider Monkey
Read
Sunday, November 24, 2019 11:24 PM EDT
Is Netflix a buy right now? The number of bullish hedge fund bets went down by 11 in recent months. Nevertheless our calculations also showed that NFLX ranked 14th among the 30 most popular stocks among hedge funds.
Whither Flexion?
Article By:
Ketan Desai
Read
Sunday, November 24, 2019 1:13 PM EDT
A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.
In this article: FLXN